Chalcogen Bonded Directly To Carbon Of The Hetero Ring Of The Quinoline Ring System Patents (Class 514/253.07)
-
Patent number: 7135466Abstract: There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (I) or pharmacologically acceptable salts or solvates thereof: wherein R1 and R2 represent hydrogen, alkyl or the like; R3, R4, R5 and R6 represent hydrogen, halogen, alkyl, alkoxy or the like; R11 and R12 represent hydrogen, alkyl, alkylcarbonyl or the like; and A represents any one of formulae (i) to (x), provided that compounds wherein R3, R4, R5 and R6 represent hydrogen and A represents group (v) wherein u is 0 (zero) and R19 represents phenyl optionally substituted by halogen, alkyl, or alkoxy are excluded.Type: GrantFiled: December 22, 2000Date of Patent: November 14, 2006Assignee: Kirin Beer Kabushiki KaishaInventors: Teruyuki Sakai, Terufumi Senga, Takayuki Furuta, Atushi Miwa
-
Patent number: 7125870Abstract: The present application describes novel isoxazoline of formula I or II: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), or a combination thereof.Type: GrantFiled: October 30, 2003Date of Patent: October 24, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Chu-Biao Xue, Thomas P. Maduskuie, Stephen E. Mercer
-
Patent number: 7115587Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.Type: GrantFiled: August 14, 2003Date of Patent: October 3, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Manoj Nerurkar, Vijay Naringrekar
-
Patent number: 7105519Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: GrantFiled: May 24, 2002Date of Patent: September 12, 2006Assignee: Avanir PharmaceuticalsInventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Mumar K. C.
-
Patent number: 7084141Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: GrantFiled: November 7, 2005Date of Patent: August 1, 2006Assignee: Avanir PharmaceuticalsInventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
-
Patent number: 7074796Abstract: The present invention relates to substituted 4-phenyl-1-piperazinyl derivatives having the formula I wherein W is C, CH or N, and the dotted line emanating from W indicates a bond when W is C and no bond when W is N or CH; R1 and R2 are independently selected from hydrogen and halogen, provided at least one of R1 and R2 is a halogen atom; R3 is selected from hydrogen, halogen, C1-6 alkyl, trifluoromethyl, C1-6 alkoxy, aryloxy, aralkoxy, hydroxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, nitro and cyano n is 2, 3, 4 or 5; X is CH2, O, S, CO, CS, SO or SO2; and Q is a group of formula wherein Z is a chain of 3 to 4 chain members; wherein the chain members are selected from C, CH, CH2, CO, N and NH, provided that only one of the chain members may be N or NH, and said chain optionally containing one or two double bonds; hvad med acyl?? R4, R5, R6, R7, R8, R9 and R10 are independently selected from hydrogen, halogen, C1-6 alkyl, trifluoromethyl, C1-6 alkoxy, hydroxy, amino, C1-6 alkylamino, di(C1-6Type: GrantFiled: June 27, 2002Date of Patent: July 11, 2006Assignee: H. Lundbeck A/SInventors: Benny Bang-Andersen, Jan Kehler, Jakob Felding
-
Patent number: 7067513Abstract: The invention relates to a novel group of phenylpiperazines having interesting pharmacological properties such as a high affinity for the dopamine D2 receptor and/or the serotonin reuptake site, and the ability to treat conditions related to disturbances in the dopaminergic and/or the serotonergic systems such as aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition, disturbances of memory, Parkinson's disease, schizophrenia, and psychotic disorders. The invention relates to a group of novel phenylpiperazine derivatives of the formula (I): wherein: X is a group of formula 1, 2, 3, 4, 5, 6, or 7 as defined in the text, m has the value 2 to 6; n has the value 0–2; R5 and R6 are independently H or alkyl (1–3C); or R5+R6 represent a group —(CH2)—p wherein p has the value 3–5, and R7 is alkyl (1–3C), alkoxy (1–3C), halogen or cyano; or R6+R7 (R7 at position 7 of the indole group) represent a group —(CH2)q wherein q has the value 2–4, and salts thereof.Type: GrantFiled: August 22, 2000Date of Patent: June 27, 2006Assignee: Solvay Pharmaceuticals B.V.Inventors: Roelof Van Hes, Johannes A. M. Van der Heijden, Cornelis G Kruse, Jacobus Tipker, Martinus T. M Tulp, Gerben M Visser, Bernard J Van Vliet
-
Patent number: 7053092Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.Type: GrantFiled: January 28, 2002Date of Patent: May 30, 2006Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Shaun Jordon, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
-
Patent number: 7049309Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.Type: GrantFiled: October 13, 2004Date of Patent: May 23, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Kenneth M. Boy, Piyasena Hewawasam, Sing-Yuen Sit, Kai Xie
-
Patent number: 6995156Abstract: Compounds of the following formula (I): where a, b, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.Type: GrantFiled: September 22, 2004Date of Patent: February 7, 2006Assignee: Schering AktiengesellschaftInventors: Judi A. Bryant, Brad O. Buckman, Imadul Islam, Raju Mohan, Michael M. Morrissey, Guo Ping Wei, Wei Xu, Shendong Yuan
-
Patent number: 6977257Abstract: The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.Type: GrantFiled: April 24, 2002Date of Patent: December 20, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Prakash V. Parab, Joyc Tianw i Chou
-
Patent number: 6969713Abstract: The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapyType: GrantFiled: December 18, 2000Date of Patent: November 29, 2005Assignee: AstraZeneca ABInventors: Premji Meghani, Colin Bennion
-
Patent number: 6960590Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: October 17, 2001Date of Patent: November 1, 2005Assignee: Merck & Co. Inc.Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
-
Patent number: 6924289Abstract: The present invention relates to lactam derivatives of the formula wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for their preparation, and to their medicinal use as selective agonists and antagonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. These compounds are useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.Type: GrantFiled: August 15, 2002Date of Patent: August 2, 2005Assignee: Pfizer IncInventor: Harry R. Howard
-
Patent number: 6919335Abstract: Compounds of the formula wherein X1 is C(O), —S(O)—, or —S(O)2—; X2 is CR3 or N; X3 is —NH—, —O—, or —S—; X4 is CR4 or N; X5 is CR5 or N; and X6 is CR6 or N are useful as inhibitors of IMPDH enzyme. Thus, these compounds can be used as therapeutic agents for IMPDH-associated disorders.Type: GrantFiled: April 23, 2001Date of Patent: July 19, 2005Assignee: Bristol-Myers Squibb Co.Inventors: Edwin J. Iwanowicz, Scott H. Watterson, T. G. Murali Dhar, William J. Pitts, Henry H. Gu
-
Patent number: 6903103Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically aType: GrantFiled: February 20, 2003Date of Patent: June 7, 2005Assignee: Les Laboratories ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
-
Patent number: 6890926Abstract: The invention relates to novel quinoline derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.Type: GrantFiled: July 20, 2001Date of Patent: May 10, 2005Assignee: Zentaris AGInventors: Peter Emig, Eckhard Günther, Jürgen Schmidt, Bernd Nickel, Bernhard Kutscher
-
Patent number: 6872723Abstract: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.Type: GrantFiled: January 17, 2003Date of Patent: March 29, 2005Assignee: WyethInventor: Henderik W. Frijlink
-
Patent number: 6861424Abstract: Compounds of the following formula (I): where a, b, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.Type: GrantFiled: June 5, 2002Date of Patent: March 1, 2005Assignee: Schering AktiengesellschaftInventors: Judi A. Bryant, Brad O. Buckman, Imadul Islam, Raju Mohan, Michael M. Morrissey, Guo Ping Wei, Wei Xu, Shendong Yuan
-
Patent number: 6838461Abstract: Compounds of the formula I in which R1, R2, R4 and R5 have the meanings indicated in claim 1, are potent 5-HT2A antagonists and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkingson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, nervous anorexia, premenstrual syndrome and/or for positively affecting compulsive behavior (obsessive-compulsive disorder, OCD).Type: GrantFiled: July 7, 2000Date of Patent: January 4, 2005Assignee: Merck Patent GmbHInventors: Henning Boettcher, Christoph Seyfried
-
Publication number: 20040235826Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: February 24, 2004Publication date: November 25, 2004Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
-
Publication number: 20040235860Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): 1Type: ApplicationFiled: June 28, 2004Publication date: November 25, 2004Applicant: Otsuka Pharmaceutical Co., Ltd.Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
-
Publication number: 20040220196Abstract: Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1 -yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.Type: ApplicationFiled: November 12, 2003Publication date: November 4, 2004Applicant: Chiron CorporationInventors: Alison Hannah, Eric Harwood, Peter Haroldsen, Carla Heise, Timothy Machajewski, Emil Samara, Xiao Shang, Jayesh Vora, Shuguang Zhu
-
Patent number: 6809093Abstract: Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds.Type: GrantFiled: December 19, 2000Date of Patent: October 26, 2004Assignee: H. Lee Moffitt Cancer & Research Institute, Inc.Inventors: Charles Raymond Degenhardt, David Joseph Eickhoff
-
Publication number: 20040204586Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity.Type: ApplicationFiled: February 13, 2004Publication date: October 14, 2004Inventors: Jagadish Sircar, Sunil Kumar K.C., Wenbin Ying
-
Patent number: 6803369Abstract: A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate with which the enzyme is in complex. Pharmaceutical compositions containing such compounds may be used to treat neoplasias or to inhibit the growth of certain cancer cells. Screening methods can be employed to identify other compounds for these uses.Type: GrantFiled: July 25, 2001Date of Patent: October 12, 2004Assignees: SmithKline Beecham Corporation, SmithKlineBeecham p.l.c.Inventors: Symon G. Erskine, Michael Gwynn, Neil David Pearson, Edwina Imogen Wilding
-
Publication number: 20040186092Abstract: The invention provides compounds of the formula: 1Type: ApplicationFiled: March 10, 2004Publication date: September 23, 2004Applicant: Roche Palo Alto LLCInventors: David Bruce Repke, Russell Stephen Stabler, Ralph New Harris
-
Publication number: 20040180902Abstract: A compound forula (I) below or a pharmaceuticaly acceptable salt or solvate thereof: wherein R1 is H or alkyl; R2 is aryl or cycloalkyl or heteroaryl; R3 is H or alkyl, wherein the alkyl group may be optionally substituted by one or more fluorine atoms; R4 is H, hydroxyalkyl, dihydroxyalkyl or hydroxyalkoxyalkyl; R5 is branched or linear alkyl, cycloalkyl, cycloalkylalkyl, aryl, or a single or fused ring aromatic heterocyclic group; R6 represents H or up to three substituents independently selected from the list consisting of: alkyl, alkenyl, aryl, alkoxy, hydroxy, halo, nitro, cyano, carboxy, carboxamido, sulphonamido, trifluoromethyl, or amino or mono- or di-alkylamino; R7 is H or halo; R8=is H or ═O; and any of R2 and R5 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy, oxo, alkyl, alkenyl, aryl, alkoxy, carboxamido, sulphonamido, trifluoromethyl, or mono- or di-alkylamino; with the proviso that said compound of formula (I) is not a compound selecteType: ApplicationFiled: April 26, 2004Publication date: September 16, 2004Inventors: Carlo Farina, Stefania Gagliardi, Giuseppe Giardina, Marisa Martinelli
-
Publication number: 20040138230Abstract: This invention relates to compounds of the formula 1 1Type: ApplicationFiled: September 12, 2003Publication date: July 15, 2004Inventors: Tonja Lynn Andreana, Stephen Sung Yong Cho, James M. Graham, Tracy Fay Gregory, Harry Ralph Howard, Brian Edward Kornberg, Sham Shridhar Nikam, Derek Andrew Pflum
-
Publication number: 20040097519Abstract: The present invention provides novel salt and hydrate crystal forms of (2R)-anti-5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride.Type: ApplicationFiled: September 10, 2003Publication date: May 20, 2004Inventors: Julie Kay Bush, Susan Marie Reutzel-Edens
-
Publication number: 20040082592Abstract: The present invention concerns compounds of formula. In a preferable embodiment, X represents O; R1 represents C1-6alkyl; cycloC3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may be replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen or C1-6alkyl; or R2 and R3 may be taken together to form —R2-R3-, which represents a bivalent radical of formula -Z4-CH2-CH2-CH2- or -Z4-CH2-CH2- with Z4 being O or NR11 wherein R11 is C1-6alkyl; and wherein each bivalent radical is optionally substituted with C1-6alkyl; or R3 and R4 may be taken together to form a bivalent radical of formula —CH2-CH2-CH2-CH2-; R5 represents hydrogen; Y represents O; and aryl represents phenyl optionally substituted with halo.Type: ApplicationFiled: August 14, 2003Publication date: April 29, 2004Inventors: Dominique Jean-Pierre Mabire, Marc Gaston Venet, Sophie Coupa, Alain Philippe Poncelet, Anne Simone Josephine Lesage
-
Publication number: 20040082579Abstract: Substituted-4-quinolones of the formula (I): wherein R1 is a straight or branched chain, saturated or ethylenically-unsaturated aliphatic hydrocarbyl group containing 1 to 18 carbon atoms which may optionally be substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR6R7, wherein each of R6 and R7 is independently selected from H and 1-6C alkyl or R6 and R7 together with the N atom to which they are attached form a saturated heterocyclic group selected from piperidino, piperazino and morpholino. R2 is a group selected from H, —OH, halo, —CHO, —CO2H and CONHR8 wherein R8 is H or a 1-6C alkyl; each of R3, R4 and R1 is independently selected form H, —CH3, —OCH3 and halo; or a non-toxic pharmaceutically-acceptable salt thereof, have use in the manufacture of a medicament for the treatment of a disease of a living animal body, including a human, which disease is responsive to the activity of an immunosuppressant.Type: ApplicationFiled: December 1, 2003Publication date: April 29, 2004Inventors: David Idris Pritchard, Barrie Walsham Bycroft, Siri Ram Chhabra, Doreen Hooi
-
Publication number: 20040062733Abstract: Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions.Type: ApplicationFiled: September 25, 2003Publication date: April 1, 2004Inventor: Jay E. Birnbaum
-
Publication number: 20040058935Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.Type: ApplicationFiled: June 16, 2003Publication date: March 25, 2004Inventors: Takuji Bando, Satoshi Aoki, Junichi Kawasaki, Makoto Ishigami, Youichi Taniguchi, Tsuyoshi Yabuuchi, Kiyoshi Fujimoto, Yoshihiro Nishioka, Noriyuki Kobayashi, Tsutomu Fujimura, Masanori Takahashi, Kaoru Abe, Tomonori Nakagawa, Koichi Shinhama, Naoto Utsumi, Michiaki Tominaga, Yoshihiro Ooi, Shohei Yamada, Kenji Tomikawa
-
Patent number: 6696480Abstract: A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include hypoxia-induced conditions. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.Type: GrantFiled: May 13, 2002Date of Patent: February 24, 2004Assignee: Brigham and Women's Hospital, Inc.Inventor: James K. Liao
-
Patent number: 6693099Abstract: Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed.Type: GrantFiled: December 19, 2000Date of Patent: February 17, 2004Assignee: The Procter & Gamble CompanyInventors: Charles Raymond Degenhardt, David Joseph Eickhoff
-
Publication number: 20040029914Abstract: Novel compounds are useful as chemotherapeutic, chemopreventative, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones.Type: ApplicationFiled: April 18, 2003Publication date: February 12, 2004Inventors: Nurulain Zaveri, Wan-Ru Chao
-
Publication number: 20040014743Abstract: The present invention is directed to novel 2-(quinolonyl)-fused heterocyclyl derivatives of the general formula (I) 1Type: ApplicationFiled: April 11, 2003Publication date: January 22, 2004Inventors: James C. Lanter, Zhihua Sui, James J. Fiordeliso
-
Publication number: 20040002501Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: ApplicationFiled: April 10, 2003Publication date: January 1, 2004Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
-
Patent number: 6656942Abstract: The present invention relates to orally active salts of compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.Type: GrantFiled: October 17, 2001Date of Patent: December 2, 2003Assignee: Merck & Co., Inc.Inventors: Mark E. Fraley, Shyam B. Karki, Yuntae Kim
-
Publication number: 20030203904Abstract: This invention comprises the novel compounds of formula (I)wherein r, s, t, Y1-Y2, R1, R2, R3, R4, R5 and R7 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.Type: ApplicationFiled: March 24, 2003Publication date: October 30, 2003Inventors: Patrick Rene Angibaud, Marc Gaston Venet, Isabelle Boelle Constance Pilatte
-
Publication number: 20030195194Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity.Type: ApplicationFiled: May 24, 2002Publication date: October 16, 2003Inventors: Federico C.A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Mumar K.C.
-
Publication number: 20030190357Abstract: The present invention relates to compositions for controlled release of a cortisol antagonist comprising at least one release rate controlling substance together with said cortisol antagonist and methods of preventing or treating metabolic syndrome, diabetes mellitis type II or symptoms or complications thereof in a mammal, which method comprises administering such a composition to said mammal in an amount effective to treat one or more of the clinical manifestations of metabolic syndrome or diabetes mellitis type II as well as complications thereof.Type: ApplicationFiled: October 30, 2002Publication date: October 9, 2003Inventors: Per Marin, Tomas Landh, Ivan Ostholm
-
Publication number: 20030158198Abstract: Compound of formula (I) 1Type: ApplicationFiled: February 11, 2003Publication date: August 21, 2003Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
-
Publication number: 20030149056Abstract: This invention provides compounds of Formula (I), represented by the structure 1Type: ApplicationFiled: November 26, 2002Publication date: August 7, 2003Applicant: American Cyanamid CompanyInventors: Allan Wissner, Hwei-Ru Tsou, Middleton Brawner Floyd, Bernard D. Johnson, Elsebe Geraldine Overbeek-Klumpers
-
Publication number: 20030130287Abstract: Compounds of the formula I 1Type: ApplicationFiled: November 5, 2002Publication date: July 10, 2003Inventors: Karl-August Ackermann, Henning Boettcher, Helmut Pruecher, Christoph V. Amsterdam, Christoph Seyfried, Hartmug Greiner, Gerd Bartoszyk, Juergen Harting
-
Publication number: 20030109523Abstract: This invention provides novel bicyclic compounds of Formula (I): 1Type: ApplicationFiled: June 6, 2002Publication date: June 12, 2003Applicant: WyethInventors: Arie Zask, Diane B. Hauze, Kenneth L. Kees, Richard D. Coghlan, John Yardley
-
Publication number: 20030105073Abstract: Quinolone derivatives of formula (1) are described: 1Type: ApplicationFiled: October 22, 2002Publication date: June 5, 2003Inventors: Alan Findlay Haughan, Hazel Joan Dyke, George Martin Buckley, Natasha Davies, Duncan Robert Hannah, Marianna Dilani Richard, Andrew Sharpe, Sophie Caroline Williams
-
Patent number: 6541470Abstract: The present invention relates to substituted 1,4-dihydro-4-oxoquinolines having antiviral activity. The substituents are present at positions 1, 2 and at least one of 5-8 positions of the quinoline ring.Type: GrantFiled: August 29, 2000Date of Patent: April 1, 2003Assignee: Maruishi Pharmaceutical Co., Ltd.Inventors: Takashi Tamura, Haruo Kuriyama, Masanobu Agoh, Yumi Agoh, Manabu Soga, Teruyo Mori
-
Publication number: 20030040513Abstract: The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.Type: ApplicationFiled: June 13, 2002Publication date: February 27, 2003Inventors: Andrew Baxter, Nicholas Kindon, Garry Pairaudeau, Bryan Roberts, Stephen Thom